JOHN J. LYNCH AICP JOHN J. LYNCH AICP JOHN J. LYNCH AICP JOHN J. LYNCH AICP JOHN J. LYNCH AICP JOHN J. LYNCH AICP
  • Home
  • About John J. Lynch
  • Services
  • Portfolio
    • Portfolio
    • References
    • Clients & Municipalities
    • Samples of Work
  • Useful Info
    • Useful Info
    • Community Resources
    • Sobriety Resources
    • News
    • Photo Library
  • Contact
News John Lynch 2017-04-21T05:57:55+00:00

News

Crain’s New York Business

RSS Crain’s New York Business

  • Op-ed: Rethinking New York’s path to decarbonization
    Late last year, the implementation of New York’s All-Electric Buildings Act was halted, and it remains in litigation. This delay should not be treated as a setback, but as an opportunity to refocus New York’s decarbonization strategy on what will actually deliver emissions reductions at scale. Until now, our climate strategy has been too narrow. Electrification […]
  • Savills agrees to buy Eastdil Secured in $1.1B deal
    Savills has agreed to acquire New York-based Eastdil Secured Holdings in a deal that values the real estate advisory business at $1.1 billion, including debt. The deal, which significantly expands the U.K. broker’s presence in the U.S. real estate market, will be funded with debt and the issue of new shares, according to a statement Thursday. Eastdil’s shareholders […]
  • Legislature rejects Hochul's surprise billing reforms, siding with doctors and hospitals
    State lawmakers rejected Gov. Kathy Hochul’s proposals to overhaul New York’s system to resolve surprise medical billing disputes, fueling a battle between insurers and medical providers over how much doctors get paid for out-of-network services.In their one-house budget proposals released Monday, the state Senate and Assembly omitted Hochul’s reforms to so-called independent dispute resolution. When […]
  • Midtown drug company to sell up to $625M in stock to fund autoimmune research
    Midtown-based Dianthus Therapeutics announced a $625 million public offering this week to raise capital for anti-inflammatory drug development.The company, which specializes in treatments for autoimmune disorders, is selling 7.3 million shares of stock at $81 per share, the company said in a statement on Tuesday. The offering is expected to close on March 12.Dianthus is […]

Planetizen: The independent resource for people passionate about planning and related fields

RSS Planetizen

JOHN J.LYNCH AICP

HOME     |      ABOUT JOHN J. LYNCH     |      CONTACT

Visitor Counter

Total: 476998

© Copyright | All Rights Reserved | Powered by Janmedia Interactive